Florian Scotte*, Carole Helissey, Vincent Launay Vacher, Thomas Lloret, Jerome Stevens and Paolo Bossi
Volume5-Issue1
Dates: Received: 2023-12-23 | Accepted: 2024-01-02 | Published: 2024-01-15
Pages: 008-012
Abstract
The evaluation of anticancer drugs safety is currently based on considering the worst Adverse Event (AE) in a particular patient. The aim of the study was to define a new method which would better describe the impact of treatment on Quality of Life (QoL), combining Patient Reported Outcomes (PROs) and the monitoring of all AEs. A comparative approach to the classic National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) classification was performed to assess the interest of monitoring Area Under the Curve (AUC) of toxicities on quality of life.
A negative impact on global health status, assessed by the VAS of EQ-5D-3L, was significantly identified for three AEs based on CTCAE grade alone versus seven when considering AUCtox assessment.
FullText HTML
FullText PDF
DOI: 10.37871/jbres1865
Certificate of Publication
Copyright
© 2024 Scotte F, et al. Distributed under Creative Commons CC-BY 4.0 
How to cite this article
Scotte F, Helissey C, Vacher VL, Lloret T, Stevens J, Bossi P. Auctox: A New Method to Evaluate the Safety of Anticancer Drugs. J Biomed Res Environ Sci. 2024 Jan 05; 5(1): 008-012. doi: 10.37871/jbres1865, Article ID: JBRES1865, Available at: https://www.jelsciences.com/articles/jbres1865.pdf
Subject area(s)
References
- Common terminology criteria for adverse events (CTCAE). 2017.
- de Mol M, Visser S, den Oudsten BL, Lodder P, van Walree N, Belderbos H, Aerts JG. Frequency of low-grade adverse events and quality of life during chemotherapy determine patients' judgement about treatment in advanced-stage thoracic cancer. Support Care Cancer. 2019 Sep;27(9):3563-3572. doi: 10.1007/s00520-019-4659-x. Epub 2019 Jan 28. PMID: 30690684; PMCID: PMC6660482.
- Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA. 2017 Jul 11;318(2):197-198. doi: 10.1001/jama.2017.7156. PMID: 28586821; PMCID: PMC5817466.
- Mooney K, Berry DL, Whisenant M, Sjoberg D. Improving Cancer Care Through the Patient Experience: How to Use Patient-Reported Outcomes in Clinical Practice. Am Soc Clin Oncol Educ Book. 2017;37:695-704. doi: 10.1200/EDBK_175418. PMID: 28561689.
- Mir O, Ferrua M, Fourcade A, Mathivon D, Duflot-Boukobza A, Dumont S, Baudin E, Delaloge S, Malka D, Albiges L, Pautier P, Robert C, Planchard D, de Botton S, Scotté F, Lemare F, Abbas M, Guillet M, Puglisi V, Di Palma M, Minvielle E. Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. Nat Med. 2022 Jun;28(6):1224-1231. doi: 10.1038/s41591-022-01788-1. Epub 2022 Apr 25. PMID: 35469070.
- Nashaan F, Al Rawi S, Alhammer M, Rabie A, Tomma AHJ. Synthesis, characterization, and cytotoxic activity of some imides from galloyl hydrazide', Eurasian Chemical Communications. 2022;4(10):966-975. doi: 10.22034/ecc.2022.340135.1453.
- Rabie AM. Potent Inhibitory Activities of the Adenosine Analogue Cordycepin on SARS-CoV-2 Replication. ACS Omega. 2022 Jan 11;7(3):2960-2969. doi: 10.1021/acsomega.1c05998. PMID: 35071937; PMCID: PMC8767658.
- Mohammed YHI, Shamkh IM, Alharthi NS, Shanawaz MA, Alzahrani HA, Jabbar B, Beigh S, Alghamdi S, Alsakhen N, Khidir EB, Alhuthali HM, Karamalla THE, Rabie AM. Discovery of 1-(5-bromopyrazin-2-yl)-1-[3-(trifluoromethyl)benzyl]urea as a promising anticancer drug via synthesis, characterization, biological screening, and computational studies. Sci Rep. 2023 Dec 20;13(1):22824. doi: 10.1038/s41598-023-44662-x. PMID: 38129413; PMCID: PMC10739849.
